文献速递皮肤肿瘤

表观遗传图谱揭示BRAF抑制剂耐药机制的分化

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.
PubMed 文献 · J Invest Dermatol · 2022-12-16

研究建立8对维莫非尼敏感/耐药的黑色素瘤细胞系,联合RNA测序与H3K27ac ChIP-seq分析,发现两类与耐药相关的表观遗传图谱:1类改变较少,2类广泛改变并集中于上皮-间质转化和缺氧通路,并在人黑色素瘤标本中验证两类结构。

要点

  • 8对维莫非尼敏感/耐药黑色素瘤细胞系中识别出两类表观遗传耐药图谱。
  • 1类耐药RNA表达改变和H3K27ac增强子标记变化较少。
  • 2类耐药转录和增强子图谱广泛改变,集中于上皮-间质转化和缺氧相关通路。

核心结论

  • 获得性BRAF抑制剂耐药过程中存在广泛且被低估的表观遗传可塑性,表现为两类不同的表观遗传图谱。

研究设计与样本

  • 研究生成8对维莫非尼敏感/耐药黑色素瘤细胞系,并进行RNA测序和H3K27ac染色质免疫沉淀测序分析。
  • 在BRAF抑制剂治疗前和复发后的人黑色素瘤标本中验证两类结构。

主要发现

  • 全局识别出两类与耐药相关的表观遗传图谱。
  • 1类耐药涉及较少的RNA表达改变,伴随较少的H3K27ac增强子标记变化。
  • 2类耐药显示转录和增强子图谱广泛改变,集中于上皮-间质转化和缺氧相关通路。
  • 观察到支撑这些转录组模式的超级增强子发生显著和动态变化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although tremendous progress has been made in targeted and immune-based treatments for advanced melanoma, there remains a substantial therapeutic failure rate. For patients with BRAF(V600)-mutant melanomas, resistance to BRAF inhibitors remains a significant survival hurdle. Although multiple compensatory mechanisms to bypass BRAF blockade have been discovered, the epigenetic patterns are still poorly characterized. In this report, we generated eight matched pairs of vemurafenib-sensitive/-resistant melanoma lines and subjected these to concurrent RNA-sequencing and H3K27ac chromatin immunoprecipitation sequencing analysis. Globally, we identified two classes of epigenetic profiles that correlate with resistance. Class 1 resistance involves fewer RNA expression alterations accompanied by fewer enhancer mark changes with H3K27ac. Class 2 resistance shows widespread alterations in transcription and enhancer profiles, which converge on epithelial‒mesenchymal transition and hypoxia-related pathways. We also observed significant and dynamic changes in superenhancers that underpin these transcriptomic patterns. We subsequently verified the two-class structure in pre-BRAF inhibitors and postrelapse human melanoma specimens. Our findings reveal a broad and underappreciated spectrum of epigenetic plasticity during acquired BRAF inhibitor resistance.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kang Y, Ji Z, Li H, et al. Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. J Invest Dermatol. 2022. PMID: 36529262. doi:10.1016/j.jid.2022.03.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。